Boston, MA 04/07/2014 (wallstreetpr) – Yesterday, Merck & Co., Inc. (NYSE:MRK) provided early discoveries associated with the relation between PD-L1 Expression and the clinical outcome of its under study Anti-PD-1 Immunotherapy, MK-3475 at AACR Annual Meeting 2014.
Initial Findings
The presentation made at the meeting aimed at establishing the relationship between PD-L1 tumor with that of clinical output of Merck & Co., Inc. (NYSE:MRK)’s monotherapy treatment MK-3475, which is aimed at treating patients with advanced non-small cell lung cancer (NSCLC) and advanced melanoma. According to the initial findings, the patients with PD-L1 negative tumors showed responses, however, early stage discoveries of the two tumor types indicates that the higher PD-L1 expression appeared to be associated with higher response rates.
The company stated that further study to establish relationship between PD-L1 and MK-345 responses as monotherapy as well as its combination with other therapies for patients with NSCLC and other tumors is already underway and will be planned for the future.
In Joint Effort WithFerring And WHO
Earlier last week, Merck & Co., Inc. (NYSE:MRK) had announced its collaboration with Ferring Pharmaceuticals along with World Health Organization to make its way further into development of latest and proprietary formulation of carbetocin, in order to limit the excess bleeding in women post child birth. The main feature of this medicine is that it could remain stable at room temperature, even in tropical and hot climates, unlike current Oxytocin that is temperature-sensitive and require steady cold temperature to be maintained.
The WHO will study the clinical outcome of Carbetocin against Oxytoxin in various countries with different temperatures. The medicine will be floated in 12 countries this year and will encompass 29,000 women across the globe. And, if the results of this study come positive then these organizations will work jointly to provide the medicine at reasonable and maintainable prices in the developing nations, which record higher maternal mortality rates.
